oncology-therpeutics-2017-scientifictracks

11 / 28

Page 31
Notes:
allied
academies
J Med Oncl Ther 2017 Volume 2 | Issue 3
International Conference on
Oncology and Cancer Therapeutics
October 30- November 01, 2017 | Chicago, USA
Comparison of efficacy and toxicity of carboplatin or cisplatin based chemo-radiotherapy treatment
among elderly locally advanced non-small cell lung cancer patients
Mohamed Sheta, Omnia Abd –El-Fattah and Hanan A Alshenawy
Tanta University Hospital, Egypt
Concurrent chemo-radiotherapy (CCRT) is the standard
management for locally advanced non-small cell lung
cancer (LA-NSCLC), but the definite choice of carboplatin
or cisplatin-based chemo-radiotherapy as a treatment for
elderly patients with LA-NSCLC has not yet been defined.
In this study, we compared the efficacy and toxicity of
Carboplatin vs. Cisplatin-based (CCRT) for elderly patients
with LANSCLC. A study was conducted on 50 elderly patients
(> 65 years) where 25 patients received. Carboplatin
(area under the curve [AUC] 2) and Paclitaxel (45 mg/m2)
administered on days 1, 8, 15, 22, 28, and 35 over a 6-week
period; concurrent thoracic radiotherapy (RT) followed by
two cycles of Paclitaxel 200 mg/m2 and Carboplatin AUC
6. The other 25 patients received 50 mg/m2 of Cisplatin
administered on days 1, 8, 29, and 36, and 50 mg/m2/day
of etoposide delivered on days 1–5 and 29–33; concurrent
thoracic RT followed by Cisplatin 50 mg/m2 and etoposide
50 mg/m2 for two additional cycles. Both groups received
thoracic RT dose ranged from 60 Gy to 70 Gy in 2 Gy per
fraction, five fractions a week over six to seven weeks.
Both Carboplatin and Cisplatin-based regimens had the
similar overall survival but the Carboplatin is less toxic when
combined with RT in elderly LA-NSCLC treated patients.
Speaker Biography
Mohamed Sheta is a Lecturer of Clinical Oncology and Nuclear Medicine and Consultant
of Clinical Oncology at Nile Hospital for Medical Insurance, Cairo in Tanta University. He
has published his papers in reputed journals.
e: